Compositions : Each uncoated bilayer tablet contains: vogliose 0.2 mg + metformin 500 mg + glimpiride 2 mg
Packing :10x10 tabs (blister pack
Voglibose (inn and usan, trade name voglib, marketed by mascot health series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications.
This is a combination of three antidiabetic medicines: glimepiride, metformin and voglibose. They work by different mechanisms to provide better control of blood sugar when single or dual therapy is not effective. Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas to lower the blood glucose. Metformin is a biguanide which lowers glucose production in the liver, delays glucose absorption from intestines and increases the body's sensitivity to insulin. Voglibose is an alpha-glucosidase inhibitor which prevents breakdown of complex sugars into simple sugars such as glucose. This prevents blood glucose from rising very high after meals.
Side effects :
Hypoglycemia (low blood sugar level), nausea, diarrhoea, taste change, flatulence, stomach pain, headache, skin rash, respiratory tract infection.